Bimekizumab (Bimzelx), developed by UCB, is emerging as a highly differentiated biologic in the global immunology market through its unique dual inhibition of IL-17A and IL-17F, delivering rapid, deep, and sustained clinical responses that surpass many existing IL-17 therapies. Since securing FDA ...Read More »
November 17, 2025
Liraglutide (Victoza), developed by Novo Nordisk, is a pioneering GLP-1 receptor agonist that has reshaped the management of type 2 diabetes and obesity through its proven efficacy in glycemic control, weight reduction, and cardiovascular risk reduction. Victoza and Saxenda both contain liraglutid...Read More »
November 14, 2025
The Triptorelin (Trelstar) market is advancing as a key segment within hormone-regulating therapeutics, supported by its long-established role in prostate cancer treatment and expanding use in central precocious puberty (CPP) and assisted reproductive technologies (ART). The market continues to sh...Read More »
November 12, 2025
The Goserelin (Zoladex) market continues to evolve, supported by its established role in hormone-dependent cancers and expanding global access to generic formulations. Demand is primarily driven by its clinical utility in prostate cancer, breast cancer, and gynecologic indications, along with sust...Read More »
November 12, 2025
NielsenIQ is a global provider of retail measurement and analytics solutions, delivering comprehensive point-of-sale data, advanced analytics, and AI-enabled insights. Serving key sectors such as consumer-packaged goods, retail, beauty, and digital commerce, NielsenIQ helps manufacturers and retai...Read More »
November 11, 2025
The U.S. independent pharmacies market size was valued at USD 172.56 billion in 2024 and is expected to expand at a CAGR of 4.26% from 2025 to 2033. The study covers more than 11,000 independent pharmacies at state level which helps to understand details regarding their location, address, ownershi...Read More »
November 11, 2025
The cell culture industry is undergoing a competitive reshaping driven by the advance of cell and gene therapies, deeper adoption of chemically defined specialty formulations, and increasing emphasis on regulatory-grade traceability. While traditional cell lines and classical media remain foundati...Read More »
November 11, 2025
Givosiran (Givlaari) is a first-in-class RNA interference (RNAi) therapy developed by Alnylam Pharmaceuticals for the treatment of acute hepatic porphyria (AHP). The drug offers disease-modifying benefits by reducing aminolevulinic acid (ALA) and porphobilinogen (PBG) levels, resulting in a marked...Read More »
November 11, 2025
The Europe dietary supplements market continues to demonstrate consistent growth, supported by aging populations, increased preventive health awareness, and a widening consumer shift toward wellness-driven lifestyles. Supplement purchases have diversified across retail ecosystems pharmacies and dr...Read More »
November 11, 2025
Selpercatinib, marketed under the brand name Retemo, represents a significant advancement in the treatment of RET-driven cancers, including non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). Approved by the FDA in 2020, Retemo is the first selective RET kinase inhibitor approve...Read More »
November 10, 2025
Sofosbuvir + Velpatasvir (Epclusa), developed by Gilead Sciences, represents a transformative milestone in hepatitis C virus (HCV) treatment as the first once-daily, pan-genotypic direct-acting antiviral (DAA) combination. By uniting a nucleotide analog polymerase inhibitor (sofosbuvir) with an NS...Read More »
November 10, 2025
Baloxavir marboxil (Xofluza), developed by Shionogi & Co., Ltd. and co-commercialized with Roche (Genentech), represents a major advancement in influenza antiviral therapy. Approved by the U.S. FDA in 2018, Xofluza introduced the first single-dose, oral treatment for acute uncomplicated influe...Read More »
November 10, 2025
Brolucizumab (Beovu) Market represents a key segment within the retinal disease treatment landscape, primarily addressing neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). Developed by Novartis, Beovu is a humanized single-chain antibody fragment (scFv) ta...Read More »
November 10, 2025
Risdiplam, marketed as Evrysdi, is an orally administered SMN2 splicing modifier developed by PTC Therapeutics in collaboration with Roche and the SMA Foundation, indicated for the treatment of spinal muscular atrophy (SMA) in patients two months and older. Approved in over 90 countries, Evrysdi h...Read More »
November 7, 2025
The global sterilization process trend report unites insights from sterilization monitoring, terminal sterilization, medical instrument washing & disinfection, and sterile barrier systems markets. It highlights a growing shift toward automation, digital monitoring, and sustainable sterilizatio...Read More »
November 7, 2025
Insulin Lispro, marketed as Humalog by Eli Lilly, is one of the leading rapid-acting insulins used in the management of Type 1 and Type 2 diabetes. Its formulation provides a rapid onset of action, making it a preferred choice for patients needing quick postprandial glucose control. Humalog’...Read More »
November 6, 2025
Luspatercept (Reblozyl), co-developed by Acceleron Pharma and Bristol Myers Squibb, represents a transformative innovation in hematology as the first erythroid maturation agent (EMA) designed to address anemia associated with lower-risk myelodysplastic syndromes (MDS) and transfusion-dependent bet...Read More »
November 6, 2025
Retatrutide (LY-3437943), developed by Eli Lilly and Company, is an innovative triple agonist targeting the GLP-1, GIP, and glucagon receptors, engineered to deliver superior weight reduction and comprehensive metabolic benefits. By simultaneously enhancing insulin sensitivity, increasing energy e...Read More »
November 6, 2025
UST is a global digital transformation solutions provider. UST serves clients across industries with a focus on digital transformation, technology consulting, and managed services. UST operates in more than 30 countries worldwide. The company serves a range of industries including healthcare, fina...Read More »
November 5, 2025
Magnetic resonance imaging (MRI) has become a cornerstone in the evaluation and management of neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia (FTD), and other dementias. MRI provides a non-invasive, radiation-free method to...Read More »
November 5, 2025